BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Edding Genor Group Holdings Limited readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Edding Genor Group Holdings Limit
 ed's drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07799129-1092@assetmemo.bio
DTSTAMP:20261121T005951Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:EDP167: Phase 2 readout est. (NCT07799129)
DESCRIPTION:EDP167\, phase 2\, Atherosclerotic Cardiovascular Disease.\nStu
 dy: Phase 2 Dose-Finding Study Evaluating the Efficacy and Safety of EDP16
 7 in Adults With Mixed Dyslipidemia\nEstimated primary completion: Novembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/edp167#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07799129
URL:https://assetmemo.bio/drug/edp167#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
